GILD · 10-Q · 2026Q3 · Full report
Product Launch and Transition
GILEAD SCIENCES, INC. · 2026-10-30 · Importance 10 · Surprise 60 · In source text
Gilead received FDA approval for Bixlenvo, a complete single-tablet HIV regimen for virologically suppressed adults, including patients switching from complex multi-tablet regimens. FDA accepted a supplemental NDA for a potential once-weekly oral Yeztugo formulation for HIV prevention, with a target action date of February 2, 2027. Hepcludex received accelerated FDA approval as the first and only FDA-approved treatment for HDV in the United States.
Key facts
- Gilead received FDA approval for Bixlenvo for HIV treatment in virologically suppressed adults, including adults switching from complex multi-tablet regimens. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Gilead received FDA approval for Bixlenvo for HIV treatment in virologically suppressed adults, including adults switching from complex… |